

Date: November 11, 2025

To,
The Manager- Listing Department,
National Stock Exchange of India Limited,
Exchange Plaza, Plot No. C/1, Block-G,
Bandra - Kurla Complex, Bandra (E),
Mumbai – 400 051

SYMBOL: REMUS

Dear Sir/Madam,

Sub.: Audio recordings of Earnings Conference Call for the half year ended September 30, 2025 pursuant to Regulations 30 and 46 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

In compliance with Regulations 30 and 46 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that the Company had Earnings Conference Call with several Analysts/Institutional Investors/Funds and other investors on the Unaudited Financial Results of the Company, for the half year ended September 30, 2025 (“Financial Results”) on November 11, 2025. Mr. Arpit Deepakkumar Shah, Managing Director and Ms. Anjali Shah, Chief Financial Officer of the Company, represented the Company at the said Earnings Conference Call.

The audio recording of said Earnings Conference Call of the Company held today i.e., Tuesday, November 11, 2025 is available on the website of the Company and can be accessed at the weblink:

<https://remuspharma.com/wp-content/uploads/2025/11/Concall-Remus-Pharmaceuticals-Limited-11112025.mp3>

No Unpublished Price Sensitive Information was shared/discussed by the Company during the Earnings Conference Call.

You are requested to take the same on record.

Thanking you.

For, Remus Pharmaceuticals Limited

Deval Patel

Company Secretary and Compliance Officer
ICSI Membership No.: A60090

Remus Pharmaceuticals Limited

REGISTERED OFFICE: 1101 to 1103, South Tower, One42, B/H Ashok Vatika, Nr. Jayantilal Park BRTS,
Ambli Bopal Road, Ahmedabad-380054, Gujarat, India.
P: 079 2999 9857

E. remus@remuspharma.com | W. www.remuspharma.com

GST NO: 24AAHCR4771P2ZQ | CIN NO: L24232GJ2015PLC084536